DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

After this recent quarterly performance and the resultant increase in stock price, an important question arises: is DXCM ...

Here are the latest rating downgrades by Seeking Alpha analysts: Palantir (NASDAQ:PLTR). Buy to hold by Victor Dergunov.

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump’s tariffs are ...

Dexcom (Nadsaq:DXCM) shares rose after hours today on first-quarter results that came in mixed compared to the consensus ...

DexCom's growth trend improved in 1Q25, but competition and shrinking market potential keep upside limited. Find out why DXCM ...

SAN DIEGO, May 01, 2025--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program SAN DIEGO, April 22, 2025--DexCom, Inc. (NASDAQ: DXCM), the global ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

Shares of DexCom Inc. DXCM surged 16.17% to $81.62 Friday, on what proved to be an all-around great trading session for the ...

Shares of DexCom jumped over 15% to pace the S&P 500's advancers Friday, a day after the maker of glucose monitoring devices ...